Roche Agrees To Court Conditions For Mircera Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.
You may also be interested in...
Roche Mircera Launch Blocked By Permanent Injunction
Ruling comes just ahead appeals-court hearing on epoetin follow-on.
Roche Mircera Launch Blocked By Permanent Injunction
Ruling comes just ahead appeals-court hearing on epoetin follow-on.
Amgen’s Anemia Drugs Weaken In First Quarter
“Trust us” on unchanged revenue guidance, CEO says.